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Eﬀects of 6 Weeks of Parenteral Cobalamin Supplementation on
Clinical and Biochemical Variables in Cats with Gastrointestinal
Disease
J.Kempf, M. Hersberger, R.H. Melliger, C.E. Reusch, and P.H. Kook
Background: Eﬀects and duration of commonly used protocols for cobalamin (Cbl) supplementation on cellular Cbl deﬁ-
ciency have not been determined in hypocobalaminemic cats.
Hypothesis/Objectives: To evaluate eﬀect of Cbl supplementation on clinical signs, serum and urine methylmalonic acid
(MMA) concentrations over 16 weeks.
Animals: Twenty client-owned hypocobalaminemic cats with enteropathy.
Methods: Prospective study. Serum Cbl and serum and urine MMA concentrations were determined prospectively in cats
at enrollment (t0), immediately before (t6), and 4 (t10) and 10 weeks (t16) after 6th Cbl injection (250 lg, IM q 7 days). Clin-
ical signs severity (activity, appetite, vomiting, diarrhea, body weight) graded at each time point and expressed as clinical dis-
ease activity score.
Results: Clinical disease activity score decreased during supplementation and increased after treatment discontinuation.
Median serum Cbl concentration increased signiﬁcantly from t0 (111 pmol/L, range 111–212) to t6 (2,332.5 pmol/L, range
123–22,730) (P < 0.01). Values at t10 were 610.5 pmol/L (range, 111–2,527) and 180.5 pmol/L (range, 111–2,262) at t16
(P < 0.01). Median baseline serum MMA concentration (372 lmol/L, range 0.39–147,000) decreased signiﬁcantly to
1.62 lmol/L (range, 0.18–806) at t6 (P < 0.01) and gradually increased to 5.34 lmol/L (range, 0.13–1,730) at t10 and
189 lmol/L (range, 0.4–983) at t16. Similar, nonsigniﬁcant, pattern observed for urine MMA concentration. Serum and urine
MMA concentrations had not normalized in 12 and 6 cats, respectively, at t6.
Conclusion and Clinical Importance: The Cbl supplementation protocol used here did not lead to complete normalization
of cellular Cbl deﬁciency in all examined cats, and biochemical improvements were transient.
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Cobalamin (Cbl), also known as vitamin B12, is awater-soluble B-group vitamin and an essential
cofactor for nucleic acid synthesis and hematopoiesis.
Its absorption requires binding proteins and speciﬁc
receptors along various parts of the gastrointestinal
tract,1 and gastrointestinal disease can lead to Cbl deﬁ-
ciency. In cell metabolism, Cbl is needed as a cofactor
for the conversion of methylmalonyl-CoA to succinyl-
CoA via methylmalonyl-CoA mutase and for remethy-
lation of homocysteine via methionine synthase. In
humans, Cbl deﬁciency causes a reduction in activity of
both of these enzymes, resulting in increases in methyl-
malonic acid (MMA) and total homocysteine concen-
trations. Measurement of these metabolites allows
assessment of availability of Cbl for cells and is the test
of choice to detect Cbl deﬁciency.2 MMA is often the
preferred marker when monitoring responses to Cbl
supplementation because homocysteine analysis usually
requires special pre-analytical procedures and concen-
trations can be inﬂuenced by lifestyle factors.2–5 In
cats, undetectable or subnormal Cbl concentrations can
also be associated with increased MMA concentrations,
but do not correlate with increased homocysteine
concentrations.6–9 Although it is not known when
depletion of cellular Cbl stores and increases in MMA
levels begin in the course of subnormal serum Cbl
concentrations, MMA is currently considered the best
indicator of Cbl status in cats.7–9 Studies examining
biochemical Cbl deﬁciency in cats have focused on
serum MMA concentration,7–11 and urine MMA
concentration has been only sporadically reported.6,12–14
In humans, a linear relationship exists between serum
and urine MMA concentrations.15 In veterinary medi-
cine, comparisons between serum and urine MMA
concentrations are lacking.
Parenteral administration of Cbl to cats with subnor-
mal Cbl values is currently considered a routine thera-
peutic procedure,7,9,11,16 and various doses and dose
frequencies have been described. It was initially recom-
mended that cats with subnormal Cbl absorption
receive 1,000 lg Cbl parenterally every 2 weeks.6 A
more recent supplementation regime suggested 250 lg
cyanocobalamin administered parenterally once weekly,
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for 6 weeks, followed by one dose every 2 weeks, for
6 weeks, and then one dose monthly.17 To our knowl-
edge, the only study that has evaluated the biochemical
response to Cbl supplementation used cats with severe
hypocobalaminemia (<74 pmol/L; lower limit of the ref-
erence range: 214 pmol/L).11 Those cats received 250 lg
cyanocobalamin parenterally, once weekly, for 4 weeks,
and serum Cbl concentration markedly increased and
serum MMA concentration signiﬁcantly decreased after
treatment.11 The most current Cbl supplementation reg-
imen suggests parenteral administration of Cbl, 250 lg
once weekly, for 6 weeks, followed by a dose 30 days
later and determination of Cbl concentration 30 days
after the last injection.a However, recommendations
beyond 4 weeks are empirical and based only on
clinical experience. Therefore, the aims of our study
were (1) to prospectively evaluate the serum concentra-
tions of Cbl and MMA and the urine concentration of
MMA in cats with hypocobalaminemia and clinical
signs of gastrointestinal disease before, during, and 4
and 10 weeks after parenteral cyanocobalamin supple-
mentation, once weekly, for 6 weeks, (2) to assess the
clinical beneﬁts during and up to 10 weeks after Cbl
supplementation, and (3) to determine the correlations
between serum Cbl concentration and serum and urine
MMA concentrations.
Materials and Methods
Animals and Study Design
This was a prospective study conducted at the Clinic for
Small Animal Internal Medicine, Vetsuisse Faculty, University of
Zurich, between December 2012 and September 2016. Cats were
enrolled in the study based on the following criteria: a history
of one or more clinical signs compatible with gastrointestinal
disease, which included diarrhea, vomiting, weight loss, and
anorexia; a serum Cbl concentration below the reference range
(225–1,451 pmol/L)18; and informed owner consent. Concurrent
disease was not considered an exclusion criterion if patients
exhibited ultrasonographic evidence of a chronic enteropathy
(generalized thickening of the muscularis layer of the small
intestines)19,20 in addition to the above-mentioned clinical signs.
Based on previous guidelines,17 all cats were supplemented with
cyanocobalaminb 250 lg once weekly IM, for 6 weeks. Baseline
samples of serum and urine were collected immediately before
the ﬁrst Cbl injection (t0) and immediately frozen at -20°C for
later measurement of MMA concentration. Serum and urine
samples were collected directly before the 6th Cbl injection (t6)
and 4 (t10) and 10 (t16) weeks after the 6th Cbl injection for
measurement of serum Cbl concentration. Aliquots were directly
frozen at 20°C for later analysis of serum and urine MMA
concentrations. All stored samples for MMA measurements were
shipped on dry ice to the laboratory, and shipping time did not
exceed 15 minutes.
To repeatedly assess the clinical status of cats undergoing Cbl
supplementation, anamnestic and clinical ﬁndings from each time
point (t0–t6, 6 Cbl injection appointments; t10, 4 weeks after the 6th
injection; t16, 10 weeks after the 6th injection) were summarized
and expressed as a clinical disease activity score, which ranged from
0 to 15. This score was based on the clinical signs used in the feline
chronic enteropathy activity index and included level of activity,
appetite, weight loss, vomiting, and diarrhea (Table 1).21 The degree
of severity for each clinical sign was scored as normal (0 points),
mild (1 point), moderate (2 points), or severe (3 points). The study
was approved by the Cantonal Veterinary Oﬃce of Zurich and con-
ducted in accordance with guidelines established by the Animal
Welfare Act of Switzerland (permission no. 211/2012).
Analyses
Serum Cbl concentration was measured with an automated
competitive binding chemiluminescence assay.c The intra- and
interassay CVs of the Cbl assay were 2.1% and 3.4%, respectively.
The reference range for serum Cbl was set at 225–1,452 pmol/L.18
Undetectable Cbl concentrations at inclusion (<111 pmol/L) were
truncated to 111 pmol/L for statistical analysis.
All serum and urine MMA levels were analyzed in the Division
of Clinical Chemistry of the University Children’s Hospital Zurich
according to accredited methods. In brief, the samples were sup-
plemented with an internal standard and precipitated, and analysis
was performed by liquid chromatography-tandem mass spectrome-
try on an Ultimate 3000 XRS UHPLC systemd with a SCIEX5500
mass spectrometere by multiple reaction monitoring. The lower
limit of quantiﬁcation for this method was 25 nmol/L in serum
and 651 nmol/L in urine. Results for MMA in urine were
expressed as mmol MMA per mol creatinine. Creatinine concen-
trations were determined by a kinetic Jaﬀe method on a DxC600
clinical chemistry analyzerf using commercial reagents. The interas-
say CVs of the analyses were 5.8% for MMA in serum and urine
and 2.7% for creatinine in urine.
The reference ranges for MMA in serum and urine in cats were
determined as 2.5 to 97.5 percentile of the measurements from 21
clinically healthy cats with normal routine laboratory results and
normal serum Cbl concentrations. These reference ranges were
0.12–0.42 lmol/L and 0.22–0.51 mmol/mol creatinine for serum
and urine concentrations of MMA, respectively.
Statistical Analysis
A Friedman test followed by a Nemenyi post hoc test was con-
ducted to compare the eﬀect of time on the repeated measures of
serum Cbl, serum MMA, and urine MMA values measured at the
four time points t0, t6, t10, and t16. A Friedman test was also used
to assess changes over time in the clinical disease activity scores (t0–
t16). Instead of a post hoc analysis, a second-order polynomial
model was ﬁtted to the clinical disease activity scores to represent
the trend over time. A second-order polynomial model was ﬁtted to
Table 1. Clinical disease activity scoring system
Score Activity Appetite Weight Loss Vomiting Diarrhea
0 Normal Normal None None Normal feces
1 Slightly decreased Slightly decreased <5% lx/wk Softer than normal, small amount
of blood/mucus, 2–3x/d
2 Moderately decreased Moderately decreased 5–10% 2–3x/wk Very soft, 4–5x/d
3 Severely decreased Severely decreased >10% >3x/wk Watery, >5x/d
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the clinical disease activity scores to represent the trend over time.
Finally, the relationship between the concentrations of serum Cbl,
serum MMA, and urine MMA were evaluated by Spearman rank
correlations. All statistical analyses and data visualization were per-
formed by statistical softwareg and graphing software.h
Results
Animals
Serum concentration of Cbl was measured in 543 cats
during the study period, and the results of 201 (37%)
were below the reference range. Although the owners of
48 cats were willing to participate in the study, only the
results of 20 cats were complete and fulﬁlled the inclu-
sion criteria. Cats were excluded when serum and/or
urine samples were missing from diﬀerent time points
or when the Cbl supplementation regimen was not car-
ried out according to the study design. Breeds included
European Shorthair (16/20), Neva Masquerade (1/20),
Siamese (1/20), Birman (1/20), and Burmese (1/20) cats.
The median age was 14 years (7.5–18), median body
weight was 3.28 kg (1.85–4.4), and median body condi-
tion score was 3 (2–5). Clinical signs present at the time
of enrollment into the study were weight loss (19/20),
vomiting (16/20), lethargy (12/20), anorexia (12/20), and
small bowel diarrhea (9/20).
Clinicopathologic Evaluation
After obtaining a clinical history, all cats underwent
a physical examination and laboratory testing including
a CBC, serum biochemistry panel, and urinalysis.
Serum thyroxine concentration was measured in 18 cats,
and four cats were diagnosed with hyperthyroidism. All
cats were evaluated for pancreatitis by the DGGR-
lipase activity assay;22 4 of 20 cats had minimally ele-
vated values (28, 32, 32, and 34 U/L; reference range,
8–26 U/L) with unclear signiﬁcance, and one cat had a
value of 73 U/L, which was considered diagnostic for
pancreatitis.23 Serum trypsinogen-like immunoreactivity
(fTLI)i was measured in all 20 cats, and none had val-
ues that were diagnostic (<8 lg/L) or suspicious (8–
12 lg/L) of exocrine pancreatic insuﬃciency. All cats
had been routinely dewormed (16/20) or had negative
fecal analysis results (4/20).
Abdominal ultrasonography carried out in 17 of 20
cats at the time of presentation showed abnormal
intestinal ﬁndings in 15. Diﬀuse thickening of the mus-
cularis layer of the small intestines was seen in 11,
mesenteric lymphadenopathy in 10, and generalized
hyperechoicity of the mucosal layer of the small intesti-
nes in 3 of the 15 cats. Histologic examination of the
intestines was performed in nine cats after collection of
full-thickness biopsy specimens during surgery (4),
endoscopic biopsy specimens (3), and specimens during
postmortem examination (4).
Definitive and Tentative Diagnoses
A deﬁnitive diagnosis of gastrointestinal tract disease
was available in 9 of 20 cats and comprised
inﬂammatory enteropathy (4), intestinal lymphoma (4;
three small cell and one large cell lymphoma), and pan-
creatitis (1). Chronic enteropathy was strongly sus-
pected in the 11 remaining cats based on clinical signs,
low serum Cbl concentration, and compatible ultra-
sonographic features of the intestines, but was not con-
ﬁrmed histologically. Concurrent hyperthyroidism was
diagnosed in four cats (three suspected of having
enteropathy, one with inﬂammatory enteropathy con-
ﬁrmed on histologic examination). The four cats with
concurrent hyperthyroidism also had biochemical evi-
dence of Cbl deﬁciency with increased serum MMA
concentration in all cats (median 75.5 lmol/L, range
0.45–1,160) and increased urine MMA concentration in
3 (median 0.17 mmol/mol creatinine, range 0.08–3.88).
Two cats had concurrent chronic kidney disease, which
was stage 2 (serum creatinine, 172 lmol/L) in one cat
and stage 3 (serum creatinine, 265 lmol/L; reference
range 98–163 lmol/L) in the other, based on the
International Renal Interest Society staging system.
Treatment
Treatment diﬀered among cats and included dietary
changes (7/20), probiotics (7/20), prednisolone (7/20),
transdermal methimazole24 (4), chlorambucil (3/20), and
antibiotics (3/20).
Concentrations of Serum Cbl, Serum MMA, and
Urine MMA
Serum Cbl concentration (Fig 1) diﬀered signiﬁcantly
over time (v2 44.68, P < 0.001). There was a signiﬁcant
increase (P < 0.01) in the median serum Cbl concentra-
tion from 111 pmol/L (range, 111–212) at t0 to
2332.5 pmol/L (range, 123–22,730) at t6, followed by a
nonsigniﬁcant (P = 0.49) decrease at t10 (median,
610.5 pmol/L, range, 111–2,527) and a signiﬁcant
decrease (P < 0.01) 10 weeks after the end of supple-
mentation (t16; median, 180.5 pmol/L, range, 111–
2,262). At t6, serum Cbl concentrations had normalized
in 19 of 20 cats. At t10 and t16, serum Cbl concentra-
tion remained within the reference range in 16 of 20
(80%) and 9 of 20 (45%) cats, respectively.
In the cat with laboratory abnormalities at t0 consis-
tent with pancreatitis (DGGR-lipase 73 U/L, Spec fPL
33 lg/L [reference range 0–3.5 lg/L], TLI 179.9 lg/L
[reference range 12–82 lg/L]) serum Cbl concentrations
increased only within the subnormal range (t0 < 111,
t6 = 123 pmol/L, t10 = 137 mmol/L, t16 = 123 mmol/
L). This cat was a 13-year-old European Shorthair with
a 1-year history of pancreatitis based on multiple
increased DGGR-lipase activities. Clinical signs at the
inclusion of this cat into the study included anorexia,
weight loss, and vomiting. Ultrasonographic ﬁndings
comprised an enlarged and mixed-echoic pancreas, a
thickened gallbladder wall, and ileocecal lymphade-
nomegaly. Increased baseline serum and urine MMA
(5.54 lmol/L and 5.5 mmol/mol creatinine at t0) had
normalized at t10 (0.29 lmol/L and 0.32 mmol/mol cre-
atinine), and were increased again at t16 (1.39 lmol/L,
Cobalamin Supplementation in Cats 3
and 4.39 mmol/mol creatinine). Clinical improvement
was noted with Cbl supplementation, diet change, and
prednisolone. The clinical disease activity score
decreased from 8 (t0) to 4 (t6, t10, and t16).
Serum MMA concentration (Fig 2) also diﬀered sig-
niﬁcantly over time (v2 10.92, P < 0.05). The post hoc
analysis showed that the median serum MMA concen-
tration decreased signiﬁcantly (P < 0.01) from
372 lmol/L (range, 0.39–147,000) at t0 to 1.62 lmol/L
(range, 0.18–806) at t6 and there was a trend toward an
increase at 4 weeks (t10 5.34 lmol/L; range, 0.13–1,730)
and 10 weeks (t16 189 lmol/L; range, 0.4–983) after the
last Cbl injection. Only 1 of 20 cats had a baseline
serum MMA concentration (0.39 lmol/L) within the
reference range. Serum MMA concentrations had nor-
malized in 8 of 20 (40%) cats at t6, and remained nor-
mal in 6 of 20 (30%) cats at t10, and in 1 of 20 (5%)
cats at t16.
Median urine MMA (Fig 3) values at t0 were
1.215 mmol/mol creatinine (range, 0.08–544). Eight of
20 cats had a baseline urine MMA concentration (me-
dian 0.15 mmol/mol creatinine, range 0.08–0.42) within
the reference range. Urine MMA concentrations
decreased in a similar fashion to serum MMA concen-
tration after Cbl supplementation at t6 (0.33 mmol/
mol creatinine; range, 0.12–1.9) and t10 (0.32 mmol/
mol creatinine; range, 0.11–3.88). Fourteen of 20
(70%) cats had normalized urine MMA values at t6,
and 12 of 20 (60%) cats had normalized urine MMA
values at t10. Urine MMA values appeared to increase
again at t16 (0.65 mmol/mol creatinine; range, 0.13–
4.39) with only 8 of 20 (40%) cats remaining in the
reference range. However, these changes did not
achieve signiﬁcance.
None of the cats with increased serum or urine
MMA values at t6 had normal baseline serum or urine
MMA values. There was a signiﬁcant negative correla-
tion between the concentrations of serum Cbl and urine
MMA (Rho 0.48, P < 0.001) and a signiﬁcant nega-
tive correlation between the concentrations of serum
Cbl and serum MMA (Rho 0.31, P < 0.05). There
was no signiﬁcant association between serum and urine
MMA values.
Clinical Signs
The median clinical disease activity score at baseline
(t0) was 4 (range, 1–11). The clinical disease activity
scores (Fig 4) diﬀered signiﬁcantly over time (v2 22.41,
P < 0.001). A polynomial regression was ﬁtted to visu-
ally represent the trend over time (R2 0.30, P < 0.001).
The trend line reﬂected a decrease in clinical disease
activity over and after the course of treatment (t0–t16)
with the lowest values at t4 and t5, after which time
(discontinuation of Cbl supplementation) the values
increased again.
Discussion
In 19 of 20 cats with Cbl deﬁciency and signs of gas-
trointestinal disease, parenteral supplementation of Cbl,
250 lg once weekly IM, for 6 weeks, led to a signiﬁcant
increase in serum Cbl concentrations followed by a
decrease at 4 and 10 weeks after the last injection. The
serum Cbl concentration at t16 was signiﬁcantly lower
than at t6. The median concentration of MMA, which is
considered a marker of cellular Cbl deﬁciency, decreased
during the 6-week period of Cbl supplementation, but
Fig 1. Combined box and scatter plot for serum Cbl concentration on a log-scale. By the Tukey method, boxes represent median and
IQR and whiskers outliers (values up to 75th percentile + 1.5 IQR). The reference range for serum Cbl concentration is indicated as a
transparent blue area with an upper and lower horizontal gray line. P values obtained by applying a Friedman test followed by a Nemenyi
post hoc test. Please note that plotted points can be indistinguishable due to individual values that are close or identical.
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the decrease was only signiﬁcant for serum MMA levels.
There was a trend for a rebound in the median concen-
trations of urine and serum MMA. This might also have
achieved statistical signiﬁcance if the cats had been fol-
lowed for longer than 10 weeks after their ﬁnal Cbl
injection. A progressive decrease in the clinical disease
activity score was seen during the period of Cbl supple-
mentation, but values increased again after the last Cbl
injection.
To our knowledge, longer-term evaluation of the Cbl
status of cats that have received 6 weeks of Cbl supple-
mentation has not been reported and was therefore a
Fig 2. Combined box and scatter plot for serum MMA concentration on a log-scale. By the Tukey method, boxes represent median and
IQR and whiskers outliers (values up to 75th percentile + 1.5 IQR). The reference range for serum MMA concentration is indicated as a
transparent blue area with an upper and lower horizontal gray line. P values obtained by applying a Friedman test followed by a Nemenyi
post hoc test. Please note that plotted points can be indistinguishable due to individual values that are close or identical.
Fig 3. Combined box and scatter plot for urine MMA concentration on a log-scale. By the Tukey method, boxes represent median and
IQR and whiskers outliers (values up to 75th percentile + 1.5 IQR). Triangles representing outliers (values greater than 75th per-
centile + 1.5 IQR). The reference range for urine MMA concentration is indicated as a transparent blue area with an upper and lower hor-
izontal gray line. P values obtained by applying a Friedman test followed by a Nemenyi post hoc test. Please note that plotted points can
be indistinguishable due to individual values that are close or identical.
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point of interest in the present study. Our data indicate
that once Cbl supplementation is discontinued in cats
with chronic enteropathy, the concentration of serum
Cbl decreases and that of MMA increases, both of
which indicate that Cbl supplementation might be nec-
essary for longer periods in cats with Cbl deﬁciency.
Very likely, the Cbl deﬁciency cannot be “ﬁxed” with-
out also resolving its underlying cause. Unfortunately,
at present it is unknown how best to determine whether
the underlying gastrointestinal disease has been con-
trolled or resolved.
In the context of the present results, it is interesting
to note that the currently advocated Cbl supplementa-
tion protocola of 6 weekly injections (250 lg/dose), fol-
lowed by one dose a month later, and retesting
1 month after the last dose seems to be designed with a
consideration for repeat testing in mind. Even if evi-
dence is currently lacking for this recommendation, the
clinical experience of the authors must have been simi-
lar to our ﬁndings in this study.
The decrease in serum Cbl concentration seen after
discontinuation of Cbl supplementation might have
been associated with insuﬃcient cellular Cbl uptake,
insuﬃcient deposition of the vitamin, or both. This
seems particularly likely considering that serum Cbl val-
ues were increased in the face of persistently elevated
MMA concentrations at t6 in more than half of the
cats. Information on cellular uptake, storage, and
release of Cbl in cats appears to be lacking. It has been
speculated that after absorption of Cbl in the ileum, the
vitamin is bound to transcobalamin, enters the entero-
hepatic circulation, and is partially excreted in bile, sim-
ilar to what has been shown in dogs.6 If that is the
case, ongoing disease processes such as inﬂammatory
enteropathy or lymphoma of the small intestines could
interfere with renewed absorption of biliary Cbl.
Another unknown variable is the saturation capacity of
Cbl transport proteins. The unsaturated Cbl-binding
capacity of plasma proteins may be exceeded when
large doses of Cbl are administered, and unbound Cbl
is lost via glomerular ﬁltration. Adequate cellular
uptake of Cbl is required for the production activity of
methylmalonyl-CoA mutase, a Cbl-dependent enzyme
located intracellularly. This in turn depends on ade-
quate binding of Cbl to transport proteins in plasma. In
humans, plasma Cbl is bound to 2 proteins, transcobal-
amin and haptocorrin (also referred to as transcobal-
amin II and I). Transcobalamin carries approximately
one quarter of the circulating Cbl, and only about 10%
of the protein is saturated with Cbl.25 Importantly, only
Cbl bound to transcobalamin (holotranscobalamin) is
available to cells. Haptocorrin is an almost fully satu-
rated Cbl-binding glycoprotein of unknown function
that carries the major part of circulating Cbl.25 It has
been shown in humans that prolonged loading with Cbl
results in a change in the total Cbl concentration but
not in the concentration of holotranscobalamin.26 Based
on the results of the present study, it is tempting to
speculate that the same holds true for cats. Unfortu-
nately, very little is known about Cbl-binding proteins
in cats,27 and relevant studies have not been carried
out. In addition, the precise Cbl requirements of cats
are not known. Experimental studies using radio-labeled
Cbl in dogs showed that the fraction of Cobalt-labeled
Cbl stored in the liver after each dose given parenterally
was highest when small doses were injected.28 Repeated
small doses of Cbl might also be needed in cats to load
the liver more eﬃciently. Interestingly, in a study on the
Fig 4. Combined box and scatter plot for the clinical disease activity score (y-axis) versus the time of measurement (x-axis). By the Tukey
method, boxes represent median and IQR, whiskers outliers (values up to 75th percentile + 1.5 IQR). Triangles representing outliers (values
greater than 75th percentile + 1.5 IQR). The dotted line represents the trend over time (derived from a second-order polynomial regres-
sion). Please note that plotted points can be indistinguishable due to individual values that are close or identical.
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eﬀects of a Cbl-deﬁcient diet in cats, urinary excretion
of MMA normalized in Cbl-deﬁcient cats when they
were given 10 lg cyanocobalamin per day parenter-
ally.13 This dose is considerably less than the one used
in the present study. Our serum MMA results at t6
could indicate that either the dose or the dose frequency
was insuﬃcient to normalize Cbl at a cellular level.
A persistent increase in serum MMA concentration
despite normalization of serum Cbl concentration has
been described, albeit in only 1 of 19 cats that received
parenteral Cbl supplementation at 250 lg once weekly,
for 4 weeks.11 Although the number of cats with
increased MMA values after discontinuation of Cbl
supplementation was not reported, the study concluded
that 250 lg of parenterally administered Cbl once
weekly, for 4 weeks, was adequate to restore normal
Cbl-dependent metabolism in many cats with
hypocobalaminemia.11 Compared with the results of
Ruaux et al. (2005),11 our baseline serum MMA values
were markedly higher (median 372 lmol/L compared
with a median of 5.4 lmol/L11) and our decrease in
MMA concentration at t6 more pronounced (median
1.62 lmol/L compared with a median of 0.4, range
0.2–7.2 lmol/L11). These diﬀerences were particularly
interesting considering that both studies used similar
reference ranges for serum MMA concentration (0.1–
0.4 lmol/L and 0.36–0.53 lmol/L11). Variances in pre-
analytical handling of samples (storage and shipment)
seem unlikely to account for major diﬀerences between
the two studies because serum MMA was recently
shown to be stable for up to 1 week when stored at
room temperature without protection from light.29 The
severity of disease, however, might have played a role
because weight loss was the major presenting complaint
in 19 of 20 cats in our study but in only 4 of 19 cats in
the other study.11
The point at which cellular Cbl deﬁciency begins to
develop is unknown. This could have contributed to the
only modest correlations between Cbl and MMA in our
study. A weak correlation between serum Cbl and
serum MMA was also found in 1 other study.9
Until now, studies in cats indicate that serum Cbl
concentrations can fall well below the reference range
before metabolic biomarkers of deﬁciency begin to
rise.7,8,11 In addition, cats can already have evidence of
Cbl deﬁciency, whereas serum Cbl values remain within
the reference range.9 A recent study showed that the
best serum Cbl concentration cutoﬀ (118 pmol/L) for
predicting elevated serum MMA concentration had a
sensitivity of only 74% and a speciﬁcity of 80%.7
It was surprising to ﬁnd no correlation between
serum and urine MMA concentrations. At t6, biochemi-
cal evidence of Cbl deﬁciency was still present in 12 cats
based on serum MMA concentration, but in only six
cats based on urine MMA concentration. Renal impair-
ment cannot be excluded as a cause for this discrepancy
because markers of glomerular ﬁltration rate were not
routinely monitored. Human patients with impaired
renal function, based on elevated plasma cystatin C val-
ues, had signiﬁcantly lower urine MMA-to-creatinine
ratios than patients with normal plasma cystatin
concentrations.30 However, this diﬀerence was very
small, and only two cats in our study were mildly azote-
mic. Moreover, a recent study in cats found no correla-
tion between the concentrations of serum creatinine and
serum MMA.9 Because of the thin nature of cats with
intestinal disease and Cbl deﬁciency, future studies
would ideally assess whether serum SDMA and MMA
correlate better than creatinine and MMA.
Although there are no data on renal clearance of cir-
culating MMA in cats, it has been shown that urinary
excretion of serum MMA relative to that of creatinine
was <1 in human patients.15,31–33 It was proposed that
an unknown percentage of serum MMA is not excreted
by the kidney, but instead is metabolized via unknown
pathways.31–33 If this theory is valid and applicable to
cats, individual diﬀerences in metabolism might have
aﬀected urinary excretion of MMA, which would
explain the discrepancy in serum and urine MMA con-
centrations. However, further studies are needed to
solve this dilemma.
Our data are in agreement with the ﬁndings of
another study,11 which concluded that cats with
hypocobalaminemia beneﬁt clinically from Cbl supple-
mentation. However, it remains inherently diﬃcult to
accurately assess the magnitude of this beneﬁcial
eﬀect because of other factors, which include the pres-
ence of underlying diseases, the absence of a deﬁnitive
diagnosis, the severity of concurrent disease, and the
eﬀect of individual treatments. Determining the beneﬁ-
cial eﬀects of Cbl supplementation can be particularly
diﬃcult in a population with varying severities of cellu-
lar Cbl deﬁciency. It was shown that human patients
with Cbl deﬁciency and only mild (0.4–0.59 lmol/L)
to moderate (0.6–2.0 lmol/L) increases in plasma
MMA concentration beneﬁted only minimally from Cbl
supplementation.34 Despite these confounding factors,
the clinical signs of cats in the present study appeared
to worsen again after the last Cbl injection, and concen-
trations of serum Cbl decreased whereas those of MMA
increased (Fig 4).
It has recently been shown that hypocobalaminemia
in cats with hyperthyroidism, in which underlying gas-
trointestinal disease is unlikely, is not a functional deﬁ-
ciency requiring supplementation.10 In contrast, all
four hyperthyroid cats in the present study also had
biochemical evidence of Cbl deﬁciency. This diﬀerence
probably is a reﬂection of variances in inclusion crite-
ria; we deliberately aimed to select cats with gastroin-
testinal disease, whereas the other study excluded cats
suspected of having or diagnosed with gastrointestinal
disease.10
Our study had some limitations. One limitation was
the inclusion of cats with more than one clearly deﬁned
disease process as well as with diﬀerent stages and
severity of disease. Furthermore, the magnitude of cellu-
lar Cbl depletion varied among cats, and MMA values
were not immediately available at enrollment, hindering
establishment of a more homogeneous population.
Moreover, the dosage regimen for Cbl supplementation
diﬀered from currently advocated regimens in that it
did not include additional Cbl injections after the
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recommended 6-week perioda. Individualized Cbl
dosage schedules might prove more eﬀective for Cbl
supplementation, and normalization of MMA levels.
However, we predicted that a prolonged study design
(ie, determination of MMA concentrations after the
currently recommended extended dosage scheme) would
have led to an even higher number of dropouts. Lastly,
our population size was relatively small, which meant
that a few outliers could have had profound eﬀects on
the statistical analysis. It took almost 4 years to be able
to include 20 cats in the present study, which underlines
the degree of diﬃculty in obtaining a larger population
size. Measurement of the postsupplementation serum
Cbl concentration was taken at the time of the 6th
injection appointment to spare owners an additional
visit to our hospital. The immediate postsupplementa-
tion values in our study (t6) therefore reﬂect the eﬀects
of ﬁve Cbl 250 lg injections, whereas the results of the
follow-up measurements reﬂect the eﬀect of six Cbl
250 lg injections.
In conclusion, our ﬁndings showed that cats with
hypocobalaminemia beneﬁt from Cbl supplementation
once weekly, for 6 weeks, but the beneﬁcial eﬀects
appear to be of relatively short duration. Although
improvements in serum Cbl concentration and biomark-
ers of Cbl status can be achieved after parenteral Cbl
supplementation, once a week, for 6 weeks, this dosage
regimen led to correction of metabolic Cbl deﬁciency in
only a subset of cats. Based on the results of our study,
follow up measurement of Cbl or serum MMA levels
appear indicated to determine if Cbl supplementation
should be continued and additional prospective studies
need to be conducted to establish whether or not cats
ever resolve their need for supplementation.
Footnotes
a http://vetmed.tamu.edu/gilab/research/cobalamin-information#-
dosing
b Cyanocobalaminum, solution injectable, 1,000 mcg/mL, Amino
AG, 5412 Gebenstorf, Switzerland
c Immulite 2000, vitamin B12, Siemens Healthcare Diagnostics
Inc, Newark, DE
d Dionex, Thermo Scientiﬁc, Waltham, MA
e SCIEX, Framingham, MA
f Beckman Coulter International S.A. Nyon, Switzerland
g R statistical program for analyses with the PMCMR and the
lme4 library
h Powerpoint for Mac (15.28); R statistical program with the
ggplot2 library
i http://vetmed.tamu.edu/gilab/service/assays/tli
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